In our present study, we identified TCF7L2 as a novel predictive marker for OS of pancreatic cancer patients, and we provided mechanisms for the metabolism effects, indicating a potential role for TCF7L2 in aerobic glycolysis regulation by targeting the EGLN2/HIF-1α axis. This evidence concerns the gene TCF7L2 and familial pancreatic carcinoma.